Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: A retrospective study

Journal of Orthopaedic Science

Volumn 7, Issue 6, 2002, Pages 637-643

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Ichimura, Shoichi ^b   Uzawa, Mitsuyoshi ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c Keiyu Orthopaedic Hospital   (Japan)

Author keywords

Alfacalcidol; Bone mineral density (BMD); Elcatonin; Osteoporosis; Vertebral fracture

Indexed keywords

ALFACALCIDOL; CALCIUM; ELCATONIN;

ADULT; AGE; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; RETROSPECTIVE STUDY; SPINE RADIOGRAPHY; VERTEBRA FRACTURE;

EID: 0036911234     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007760200114     Document Type: Article

References (26)

1. 3, parathyroid hormone, and glucocorticoids. Met Bone Dis 1984;5:229-34.
2. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
3. 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
4. 3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 1997;20:557-62.
5. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporosis Fractures study. Am J Med 2000;109:267-76.
6. Fujita T, Orimo H, Inoue T, et al. Double-blind multicenter comparative study with alfacalcidol of etidronate disodium (EHDP) in involutional osteoporosis. Clin Eval 1993;21:261-302 (in Japanese).
7. Fujita T, Fujii Y, Goto B, et al. A 3-year comparative trial in osteoporosis treatment: Effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 1997;15:223-6.
8. Garnero P, Sornary-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 2000;15:1526-36.
9. Iwamoto J, Takeda T, Otani T, et al. Age-related changes in cortical bone in women: Metacarpal bone mass measurement study. J Orthop Sci 1998;3:90-4.
10. Iwamoto J, Takeda T, Ichimura S, et al. Age-related changes in cortical bone in men: Metacarpal bone mass measurement study. J Orthop Sci 2000;5:4-9.
11. Lian J, Stewart C, Puchacz E, et al. Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. Proc Natl Acad Sci USA 1989;86:1143-7.
12. Maggio D, Pacifici R, Cherubini A, et al. Age-related cortical bone loss at the metacarpal. Calcif Tissue Int 1997;60:94-7.
13. Melton LJ III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-91.
14. 3. Bone Miner 1987;3:47-52.
15. Orimo H, Fujita T, Onomura T, et al. Clinical evaluation of Ea-0167 (menatetrenone) in the treatment of osteoporosis: phase III double-blind multicenter comparative study with alfacalcidol. Clin Eval 1992;20:45-100 (in Japanese).
16. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370-6.
17. Orimo H, Morii H, Inoue T, et al. Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 1996;14:73-8.
18. Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998;16:139-50.
19. Ringe JD, Welzel D. Salmon calcitonin in the therapy of cortico-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9.
20. Rosen CJ. Pre-emptive bone strikes in prevention of osteoporosis. Lancet 1998;351:927-8.
21. Shiraishi A, Takeda S, Masaki T, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. J Bone Miner Res 2000;15:770-9.
22. 3. Bone Miner 1993;20:223-34.
23. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfa-calcidol in Japanese patients with osteoporosis. Osteoporos Int 1999;10:183-92.
24. 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15;515-21.
25. Tanizawa T, Imura K, Ishii Y, et al. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: A retrospective study. Osteoporos Int 1999;9:163-70.
26. Yoshimura N, Hashimoto T, Sakata K, et al. Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: The Taiji study. Calcif Tissue Int 1999;65:198-202.